Pursue either isoform-specific RGS6 engineering or pharmacologic RGS6 activation to enhance protective signaling. The debate strongly argues these are premature because core isoform biology, target engagement, selectivity, and safety are not established.
Restore RGS6 in substantia nigra pars compacta dopaminergic neurons after established alpha-synuclein pathology to test whether RGS6 loss is not only necessary but therapeutically reversible. The decisive experiment is delayed intervention in PFF or AAV-SNCA models with unbiased stereology, terminal preservation, dopamine physiology, and catalytically dead RGS6 controls.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
RGS6Unspecified Mechanismneurodegeneration
Convergent signals
RGS6 recurs across 2 selected hypotheses with aligned directionality in unspecified mechanism.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
1/11
dimensions won
RGS6 isoform switching or small-molecule
11/11
dimensions won
AAV-mediated RGS6 re-expression in SNpc
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.11
0.48
Evidence
0.08
0.42
Novelty
0.71
0.74
Feasibility
0.12
0.58
Impact
0.18
0.55
Druggability
0.10
0.62
Safety
0.16
0.28
Competition
0.52
0.63
Data
0.09
0.52
Reproducible
0.11
0.46
KG Connect
0.50
0.50
Score Breakdown
Dimension
RGS6 isoform switching or smal
AAV-mediated RGS6 re-expressio
Mechanistic
0.110
0.480
Evidence
0.080
0.420
Novelty
0.710
0.740
Feasibility
0.120
0.580
Impact
0.180
0.550
Druggability
0.100
0.620
Safety
0.160
0.280
Competition
0.520
0.630
Data
0.090
0.520
Reproducible
0.110
0.460
KG Connect
0.500
0.500
Evidence
RGS6 isoform switching or small-molecule RGS6 activation as
No evidence citations yet
AAV-mediated RGS6 re-expression in SNpc after pathology onse
No evidence citations yet
Debate Excerpts
RGS6 isoform switching or small-molecule RGS6 acti
4 rounds · quality: 0.54
Theorist
# Therapeutic Hypotheses: RGS6 Upregulation & D2 Autoreceptor Modulation in Established Parkinson's Models
---
## Hypothesis 1: AAV-Mediated RGS6 Overexpression in Substantia Nigra Rescues Establish...
Skeptic
Several of these hypotheses over-interpret a loss-of-function phenotype as if it implied therapeutic gain-of-function, and several supporting citations are mismatched to the claims. After checking the...
Domain Expert
# Feasibility Assessment: RGS6 and D2 Autoreceptor Modulation in Established PD Models
## Executive Summary
The SKEPTIC's analysis effectively deflates most of these hypotheses, leaving two core tes...
Synthesizer
{
"ranked_hypotheses": [
{
"title": "AAV-mediated RGS6 re-expression in SNpc after pathology onset",
"description": "Restore RGS6 in substantia nigra pars compacta dopaminergic neuro...
AAV-mediated RGS6 re-expression in SNpc after path
4 rounds · quality: 0.54
Theorist
# Therapeutic Hypotheses: RGS6 Upregulation & D2 Autoreceptor Modulation in Established Parkinson's Models
---
## Hypothesis 1: AAV-Mediated RGS6 Overexpression in Substantia Nigra Rescues Establish...
Skeptic
Several of these hypotheses over-interpret a loss-of-function phenotype as if it implied therapeutic gain-of-function, and several supporting citations are mismatched to the claims. After checking the...
Domain Expert
# Feasibility Assessment: RGS6 and D2 Autoreceptor Modulation in Established PD Models
## Executive Summary
The SKEPTIC's analysis effectively deflates most of these hypotheses, leaving two core tes...
Synthesizer
{
"ranked_hypotheses": [
{
"title": "AAV-mediated RGS6 re-expression in SNpc after pathology onset",
"description": "Restore RGS6 in substantia nigra pars compacta dopaminergic neuro...